Improvement in patient-reported symptomscreen scores among ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 1-year results from the casting clinical trial

Authors
Category Primary study
JournalNeurology
Year 2020
This article has no abstract
Epistemonikos ID: 2d4f09eed86803214c0f0866283b1b75dbd57b11
First added on: Feb 12, 2025